EDTA has been recommended as the anticoagulant of choice for hematological testing because it allows the best preservation of cellular components and morphology of blood cells. However, in EDTA induced platelet clumping and platelet agglutination result in low platelet count on automated hematology analyzers. The phenomenon was called EDTA dependent pseudo-thrombocytopenia (EDTA-PTCP) We report a case of EDTA-PTCP in a pneumonia due to 2019 novel coronavirus disease (COVID- 19). A 62 year old male patient was diagnosed with severe pneumonia due to COVID 19. At the presentation, he did not have any signs of bleeding, and the platelet count was normal, he was initially treated with enoxaparin. After 5 days, his platelet counts gradually decreased, heparin induced thrombocytopenia was a suspected diagnosis, so enoxaparin stopped immediately. However, the platelet counts slowly increased and the patient did not have any signs of bleeding.The peripheral blood smear was performed, it showed a platelet aggregation. The whole blood sample was recollected in tube used sodium citrate as the anticoagulant and warmed up at 37C before being tested by Automatic Blood Analyzer Machine , result showed number of platelets was normal. Thus, EDTA-dependent pseudothrombocytopenia has no clinical significance and a peripheral blood smear in all cases of thrombocytopenia is essential, thereby providing measures to accurately determine the amount of thrombocytopenia. . From this case report, it is possible that in COVID19 patients, antibodies that react with platelet antigens are altered by EDTA, causing the EDTA - pseudothrombocytopenia.
Lọc theo danh mục
Lượt truy cập :
20,897,237
Xem toàn văn